Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase II Trial of Eribulin plus Gemcitabine in Previously Treated Advanced Liposarcoma or Leiomyosarcoma
KCT0003547Phase 2Completed
- Sponsor
- Chong Kun Dang
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin, gemcitabine in Liposarcoma, leiomyosarcoma (LMS), sponsored by Chong Kun Dang. Started Mar 2018; status: completed.
02
Drugs
eribulingemcitabine
03
Conditions
Liposarcomaleiomyosarcoma (LMS)
Beyond the preview
Go deeper on KCT0003547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003547.